2. Search Result
Search Result
Results for "

CD69

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

1

Biochemical Assay Reagents

6

Inhibitory Antibodies

4

Recombinant Proteins

5

Antibodies

4

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-155978A
    RDN2150 TFA
    1 Publications Verification

    		 Tyrosinase Inflammation/Immunology
    RDN2150 (Compound 25) TFA is a ZAP-70 inhibitor (IC50: 14.6 nM). RDN2150 TFA covalently binds to the C346 residue of ZAP-70. RDN2150 TFA inhibits the expression of CD25 and CD69, and inhibits CD4 + T cell activation. RDN2150 TFA can be used for research of psoriasis .
    RDN2150 TFA
  • HY-160229
    ssRNA40 sodium

    R-1075 sodium

    		 Toll-like Receptor (TLR) MyD88 Caspase Reactive Oxygen Species (ROS) Autophagy Pyroptosis HIV Infection Neurological Disease
    ssRNA40 sodium (R-1075 sodium) is a single-stranded RNA40 derived from HIV-1. ssRNA40 sodium activates the TLR7, TLR8, TLR2, RIG-I, MDA5, MyD88, Caspase-3, IRE1α, NLRP3 inflammasome and IRF7 signaling pathways. ssRNA40 sodium alters mRNA expression in neutrophils, induces pro-inflammatory cytokines, ROS, autophagy (autophagy), pyroptosis (pyroptosis), neuronal death, neurodegeneration, aggregate formation and NK cell activation. ssRNA40 sodium activates the expression of CD62L, CD11b, CD69, MX1, OAS1, ATG7, LC3B and XBP1 in immune cell and neuronal populations. ssRNA40 sodium causes cortical neuron loss and axonal damage in mice in a TLR7-dependent manner. ssRNA40 sodium can be used in research on HIV-1 infection, neurodegeneration, COVID-19 and HIV-associated neurological disorders .
    ssRNA40 sodium
  • HY-P990358
    Anti-CD7 Antibody

    		Transmembrane Glycoprotein Inflammation/Immunology
    Anti-CD7 Antibody is a recombinant monoclonal antibody targeting CD7, and it is mainly used as a reference antibody.
    Anti-CD7 Antibody
  • HY-P990265
    Anti-Mouse CD69 Antibody (CD69.2.2)

    		Transmembrane Glycoprotein Orthopoxvirus Infection Others Inflammation/Immunology Cancer
    Anti-Mouse CD69 Antibody (CD69.2.2) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to mouse CD69. Anti-Mouse CD69 Antibody (CD69.2.2) causes CD69 to be internalized but does not deplete CD69 + cells. Anti-Mouse CD69 Antibody (CD69.2.2) can be used for the researches of cancer, infection, inflammation and immunology, such as RMA-S tumor, arthritis and vaccinia virus (VACV) infection .
    Anti-Mouse CD69 Antibody (CD69.2.2)
  • HY-108944
    LYP-IN-1

    		SHP2 SHP1 Phosphatase Inflammation/Immunology
    LYP-IN-1 is a potent, selective and specific LYP inhibitor with a Ki and an IC50 of 110 nM and 0.259 μM, respectively. LYP-IN-1 also has selectivity for a large panel of PTPs, such as SHP1 (IC50=5 μM) and SHP2 (IC50=2.5 μM). LYP-IN-1 exhibits highly efficacious cellular activity in T- and mast cells. LYP-IN-1 can be used for the study of autoimmune disorders . LYP-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    LYP-IN-1
  • HY-18164
    TASP0277308

    		LPL Receptor Inflammation/Immunology
    TASP0277308 is a highly selective S1P1 antagonist. TASP0277308 possesses immunomodulatory activities, including lymphopenia, a block in T cell egress from the thymus, marginal zone B cell displacement, and the upregulation of CD69 expression on lymphocytes. TASP0277308 can be used for the research of collagen-induced arthritis in mice .
    TASP0277308
  • HY-RS17265
    Cd69 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Cd69 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cd69 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cd69 Mouse Pre-designed siRNA Set A
    Cd69 Mouse Pre-designed siRNA Set A
  • HY-RS02262
    CD69 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    CD69 Human Pre-designed siRNA Set A contains three designed siRNAs for CD69 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CD69 Human Pre-designed siRNA Set A
    CD69 Human Pre-designed siRNA Set A
  • HY-155978
    RDN2150

    		Tyrosinase Inflammation/Immunology
    RDN2150 (Compound 25) is a ZAP-70 inhibitor (IC50: 14.6 nM). RDN2150 covalently binds to the C346 residue of ZAP-70. RDN2150 inhibits the expression of CD25 and CD69, and inhibits CD4 + T cell activation. RDN2150 can be used for research of psoriasis .
    RDN2150
  • HY-RS23719
    Cd69 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Cd69 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cd69 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cd69 Rat Pre-designed siRNA Set A
    Cd69 Rat Pre-designed siRNA Set A
  • HY-P990357
    Anti-CD69 Antibody

    		Transmembrane Glycoprotein Inflammation/Immunology
    Anti-CD69 Antibody is a human-derived antibody expressed in CHO, targeting CD69. The predicted molecular weight (MW) of Anti-CD69 Antibody is 150 kDa. The isotype control for Anti-CD69 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CD69 Antibody
  • HY-159123
    KHK-6

    		MAP4K Cancer
    KHK-6 is an inhibitor for serine/threonine kinase hematopoietic progenitor kinase 1 (HPK 1) with an IC50 of 20 nM. KHK-6 enhances CD3/CD28-induced cytokine production, enhances CD69, CD25 and HLA-DR markers on CD4+ and CD8+ T cells, and enhances T cell-mediated killing activity of SKOV3 and A549 cells .
    KHK-6
  • HY-152201
    BTK-IN-18

    		Btk Cancer
    BTK-IN-18 is a potent, reversible BTK inhibitor with an IC50 of 0.002 µM. BTK-IN-18 inhibits both CD69 and CD86 in vivo .
    BTK-IN-18
  • HY-145373
    BMS-986143

    		Btk Inflammation/Immunology
    BMS-986143 is an orally active, reversible BTK inhibitor with an IC50 of 0.26 nM. BMS-986143 also inhibits TEC, BLK, BMX, TXK FGR, YES1, ITK with IC50s of 3 nM, 5 nM, 7 nM, 10 nM, 15 nM,19 nM, 21 nM, respectively. BMS-986143 can be used for the research of autoimmune diseases .
    BMS-986143
  • HY-NP078A
    Pisum Sativum Agglutinin (FITC)

    PSA (FITC)

    		 Biochemical Assay Reagents CD3 Inflammation/Immunology Endocrinology
    Pisum sativum Agglutinin (PSA) FITC is a plant lectin conjugated with FITC (HY-66019). Pisum sativum Agglutinin FITC serves as an acrosome stain for detecting the acrosomal status of sperm. Pisum sativum Agglutinin exhibits lymphocyte mitogenic and immunomodulatory activities .
    Pisum Sativum Agglutinin (FITC)
  • HY-145884
    BTK-IN-8

    		Btk Inflammation/Immunology
    BTK-IN-8 is a potent and selective peripheral covalent BTK inhibitor (IC50=0.22 nM; Kd=0.91 nM). BTK-IN-8 has good whole blood CD69 cellular potency (IC50=0.029 µM) .
    BTK-IN-8
  • HY-P991479
    Amtabafusp alfa

    GS-8588

    		 HIV CD3 Infection
    Amtabafusp alfa (GS-8588) is an envelope-targeting bispecific T-cell engager for HIV treatment. Amtabafusp alfa redirects effector T cells by binding to CD3 via a humanized anti-CD3 Fab domain and to HIV envelope proteins via an engineered CD4 domain 1 variant. Amtabafusp alfa exhibits potent, broad-spectrum activity against a variety of HIV isolates and specifically kills HIV-infected cells. Amtabafusp alfa can be used for research on HIV infection .
    Amtabafusp alfa
  • HY-181884
    TLR9-IN-3

    		Inflammation/Immunology
    TLR9-IN-3 is a TLR9 antagonist with an IC50 of 0.4 μM. TLR9-IN-3 shows selectivity for TLR4 and TLR8, and inhibits CD69 activation in human whole blood with a corresponding IC50 of 1.1 μM. TLR9-IN-3 can be used in research related to pulmonary fibrosis .
    TLR9-IN-3
  • HY-P991900
    LY3541860

    		CD19 Inflammation/Immunology
    LY3541860 is a selective anti-CD19 antibody that both binds human CD19 with high affinity and selectively binds human B cells (Kd values: 76.8 pM and 94.5 nM for humans and cynomolgus monkeys, respectively). LY3541860 inhibits CpG-induced CD69 expression (IC50 = 0.006 nM). LY3541860 exhibits potent B cell inhibitory activities. LY3541860 can inhibit both BCR- and TLR-induced human B cell activation. LY3541860 can be used for the research of autoimmune diseases .
    LY3541860
  • HY-182503
    GP515

    		Adenosine Kinase Others Inflammation/Immunology
    GP515 is a potent and selective adenosine kinase inhibitor with a human IC50 of 4 nM. GP515 exerts tissue protective effects, produces long-lasting hepatic microcirculation effects after hemorrhagic shock, and induces dose- and time-related VEGF mRNA and protein expression in normoxic rat myocardial myoblasts, with additive VEGF increases during mild hypoxia and no effect during severe hypoxia. GP515 suppresses IFNγ synthesis and CD69 expression in DSS-induced colitis. GP515 also shows a dose-dependent suppression of TNF-α production with an IC50 of 80 μM and can be reversed in the presence of the cAMP antagonist (Rp)-cAMPS. Combinations of GP515 with either adenosine or rolipram led to an additive inhibition of TNF-α synthesis. GP515 can be used for the research of hemorrhagic shock .
    GP515
  • HY-P992375
    HuMax-IL15

    		Interleukin Related Inflammation/Immunology
    HuMax-IL15 is a human IgG1 monoclonal antibody against IL-15. HuMax-IL15 is applicable to the research of rheumatoid arthritis. The recommended isotype control is human IgG1 kappa (HY-P99001) .
    HuMax-IL15

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: